Tesamorelin + Ipamorelin (Tesa/Ipa)

Tesa/Ipa is not a single drug. It is a pre-mixed powder vial of two peptides: tesamorelin, a lab-made copy of the body's own growth-hormone trigger (GHRH), and ipamorelin, which nudges the pituitary gland through a different switch (the ghrelin receptor). Seller listings show different ratios, such as 10mg tesamorelin with 3mg or 5mg ipamorelin. It is sold by online 'research peptide' shops, labelled for research use only. This is not Egrifta, the licensed US tesamorelin medicine; it is unlicensed powder of unknown quality.

It borrows the reputation of both parts. Tesamorelin is the one growth-hormone peptide with big, proper trials and a US licence, so sellers lean on its 'proven belly-fat burner' label. Ipamorelin is marketed as the 'clean' growth-hormone pulse that does not push up hunger or stress hormones much. Put together, the pitch is the same two-levers logic as CJC-1295 + ipamorelin, but with a 'proven' name on the label.

Tesamorelin's Grade A is real but narrow: it covers shrinking deep belly fat in people with HIV-associated lipodystrophy, where large placebo-controlled trials led to its US approval, and even there the fat comes back after stopping. That grade does not transfer to fat loss, bodybuilding or anti-ageing in healthy adults, where there is no comparable trial evidence. Ipamorelin reliably raises growth hormone in people, but its only efficacy trial (restarting the gut after bowel surgery) was negative, and nothing it is sold for has been shown in humans. Nobody has tested the two together. And the vial is not the medicine from those trials: it is grey-market powder whose identity, purity and sterility nobody checks. Raising growth hormone also has real trade-offs, including higher blood sugar, fluid retention and a theoretical worry about tumour growth.

Neither is a licensed medicine in the UK. Tesamorelin is approved in the US (Egrifta) but not by the MHRA; in the UK it is only obtainable as an unlicensed medicine through a prescriber, or illegitimately as a grey-market 'research chemical'. Ipamorelin has no marketing authorisation anywhere. Selling either for human use without authorisation breaches the Human Medicines Regulations 2012. Both tesamorelin and ipamorelin are prohibited at all times under WADA category S2.